Investment
Features
FeesSafety
Academy
More
Pluang+

Rio Tinto invests A$1.1B to secure Tomago smelter's future with 100% renewable power by 2033

Market News
13 Aug 2026
Proactive Investors
View Source
Bullish
pluang ai news

Rio Tinto has secured a long-term power agreement for its Tomago aluminium smelter in Australia, ensuring operations until 2038 with a transition to 100% renewable electricity by 2033. The A$1.1 billion investment includes A$100 million for decarbonisation, expected to cut carbon emissions by 7.1 million tonnes annually. This deal supports Australian manufacturing, skilled jobs, and supply stability, while aligning with Rio Tinto's goal to halve emissions by 2030. The new 10-year power purchase agreement starts after the current contract ends in 2028.

More News

Rubrik director Yvonne Wassenaar sold 721 shares at $75 before stock rally began.

Rubrik director Yvonne Wassenaar sold 721 shares at $75 before stock rally began.

Yvonne Wassenaar, a director at Rubrik, sold 721 shares at a price of $75 each just before the company's stock experienced a significant rally. This sale occurred ahead of the stock's upward movement, which may be of interest to investors tracking in...

Market News
Bearish
1 hour ago
Gold and silver prices rise as weaker U.S. retail sales boost hopes for Fed rate pause in September

Gold and silver prices rise as weaker U.S. retail sales boost hopes for Fed rate pause in September

Gold and silver prices increased in early U.S. trading following a surprise 0.6% drop in July retail sales, which strengthened market expectations that the Federal Reserve may hold interest rates steady in September. The softer consumer data, combine...

Market News
Neutral
4 hours ago
Clover Health posts strong Medicare Advantage growth, profit, and outlook, keeping a strong buy rating.

Clover Health posts strong Medicare Advantage growth, profit, and outlook, keeping a strong buy rating.

Clover Health (CLOV) reported significant growth with a 48% year-over-year increase in Medicare Advantage membership, 56% revenue growth, and 54% gross profit growth. This performance is driven by cohort maturation and the Clover Assistant platform. ...

Company Fundamentals
Bullish
4 hours ago
Celcuity remains a Buy as FDA approval and strong trial data boost confidence in its cancer drug launch.

Celcuity remains a Buy as FDA approval and strong trial data boost confidence in its cancer drug launch.

Celcuity Inc. is rated a Buy following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its rapid inclusion in NCCN Category 1 guidelines, which reduce risks for clinical and commercial adoption. The company has made significant upfront ...

Market News
Bullish
4 hours ago
Tapestry shares drop 16.5% post-earnings despite beating Q4 estimates, raising questions on guidance.

Tapestry shares drop 16.5% post-earnings despite beating Q4 estimates, raising questions on guidance.

Tapestry, owner of Coach and Kate Spade, beat Q4 revenue and earnings expectations but saw its stock fall 16.5% due to cautious FY2027 guidance. Revenue rose 8.9% to $1.88 billion and EPS beat estimates at $1.32, with margin expansion. However, the g...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App